SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, May 11, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the JMP Securities Life Sciences Conference on Tuesday, May 16, 2023 at 10:00 a.m. Eastern Time in New York.
David R. Parkinson, President and Chief Executive Officer of ESSA Pharma; Peter Virsik, ESSA's Chief Operating Officer; and David S. Wood, ESSA's Chief Financial Officer, will host and participate in one-on-one meetings.
A live webcast of the JMP Securities presentation can be accessed in the Investors/Events & Presentations section of ESSA's website at www.essapharma.com. Following the event, the webcast will be archived on the ESSA website for 90 days.
ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com and follow us on Twitter under @ESSAPharma.
Last Trade: | US$0.20 |
Daily Volume: | 0 |
Market Cap: | US$9.320M |
October 06, 2025 February 11, 2025 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load